Exclusive Summary

• Sodium hyaluronate eye drops, as a first-line treatment recommended by guidelines for the high global prevalence of dry eye disease (over 30%), possess a huge potential market.
• Although the original patent has long expired with numerous generics, there is still demand for differentiation, and Chinese suppliers' cost and quality advantages can offer competitive alternatives.
• The product has mature registration experience in most global markets and, with international quality certifications, can quickly connect with partners seeking high-value products.
• Sodium hyaluronate is listed in the WHO Essential Medicines List, and its wide acceptance and lower cost provide significant potential for widespread adoption in developing and emerging markets.